12.16.15
Sensient Technologies announced the appointment of Mario Ferruzzi and Donald Landry to its Board of Directors.
Dr. Ferruzzi is a professor in the Departments of Food Science and Nutrition Science at Purdue University. Prior to joining Purdue, Dr. Ferruzzi was a Development Scientist with Nestle. He is recognized as an international expert in analytical chemistry and its application in food and nutrition.
Dr. Landry is the Samuel Bard Professor and chair of the Department of Medicine at Columbia University’s College of Physicians and Surgeons. He also serves as the director of the Division of Experimental Therapeutics at the school. Dr. Landry has been at Columbia since 1985. He currently serves as a director of Tonix Pharmaceutical Holding Corp, a publicly traded company listed on the NASDAQ. Dr. Landry was a co-founder of L&L Technologies and of Vela Pharmaceuticals. Both companies developed medications for central nervous system conditions.
“These individuals bring valuable leadership experience and technical skills to Sensient’s Board of Directors” said Sensient chairman Kenneth Manning. “I look forward to having the benefit of their inputs and advice as we work to deliver value for our shareholders. With these two additions, we have now added six new directors to our board in the last four years.”
Dr. Ferruzzi is a professor in the Departments of Food Science and Nutrition Science at Purdue University. Prior to joining Purdue, Dr. Ferruzzi was a Development Scientist with Nestle. He is recognized as an international expert in analytical chemistry and its application in food and nutrition.
Dr. Landry is the Samuel Bard Professor and chair of the Department of Medicine at Columbia University’s College of Physicians and Surgeons. He also serves as the director of the Division of Experimental Therapeutics at the school. Dr. Landry has been at Columbia since 1985. He currently serves as a director of Tonix Pharmaceutical Holding Corp, a publicly traded company listed on the NASDAQ. Dr. Landry was a co-founder of L&L Technologies and of Vela Pharmaceuticals. Both companies developed medications for central nervous system conditions.
“These individuals bring valuable leadership experience and technical skills to Sensient’s Board of Directors” said Sensient chairman Kenneth Manning. “I look forward to having the benefit of their inputs and advice as we work to deliver value for our shareholders. With these two additions, we have now added six new directors to our board in the last four years.”